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EO9 (Apaziquone) is a bioreductive drug that has a chequered history. It 
underwent clinical trial but failed to show activity in phase II clinical trials when 
administered intravenously. Poor drug delivery to tumours caused by a 
combination of rapid pharmacokinetic elimination and poor penetration 
through avascular tissue are the major causative factors responsible for 
EO9’s poor efficacy. Based upon an understanding of why EO9 failed, a 
further clinical trial against patients with superficial transitional cell carcinoma 
of the bladder was conducted. The rationale for this was that intravesical 
administration directly into the bladder would circumvents the drug delivery 
problem and any drug reaching the blood supply would be rapidly cleared 
thereby reducing the risk of systemic exposure. EO9 was well tolerated and 
clinical activity against marker lesions was recorded in both phase I and II 
clinical trials. This article charts the pharmacological history of EO9 and 
discusses the potential implications that ‘the EO9 story’ has for the 
development of other loco-regional therapies.  
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EO9 (3-hydroxy-5-aziridinyl-1-methyl-2 (1H-indole-4,7-dione)prop-β-en-α-ol) 
is a prodrug that belongs to a class of anti-cancer agents known as 
bioreductive drugs. Various chemical classes of bioreductive drugs have been 
developed (Denny, 2004; Hay et al., 2008; Hay et al., 2007a; Hay et al., 
2007b; Milbank et al., 2009; Tercel et al., 2009) and all require enzymatic 
reduction by various oxidoreductases in order to generate cytotoxic 
metabolites. This activation process is reversed in the presence of oxygen 
and these agents have preferential activity against hypoxic tumour cells 
(McKeown et al., 2007; Stratford et al., 1998). Selectivity is determined by the 
presence of elevated levels of reductases in tumours and the absence of 
oxygen (figure 1). At the time EO9 was developed, these compounds 
represented a from the classical way anticancer drugs were developed of 
identifying active compounds first and then identifying mechanisms of action 
towards targeted therapeutic agents that selectively exploit aspects of tumour 
biochemistry and physiology.  
 
EO9 was originally developed at the University of Amsterdam in the mid 
1980’s (Oostveen et al., 1987). The project was initially sponsored by the 
Dutch Cancer Society and a series of 90 indolequinone (given the name EO) 
derivatives of Mitomycin C were developed, the ninth of which was EO9 
(figure 1). Preclinical and clinical evaluation was co-ordinated by the New 
Drug Development Office of the European Organisation for the Research and 
Treatment of Cancer (EORTC) and a number of laboratories belonging to the 
Screening and Pharmacology (SPG) and Pharmacology and Molecular 
Mechanism (PAMM) groups across Europe played key roles in the 
pharmacological evaluation of these compounds. Clinical evaluation of EO9 
was halted by lack of efficacy in phase II trials (Dirix et al., 1996; Pavlidis et al., 
1996). Based upon an understanding of why EO9 failed, a further phase I/II 
clinical trial against superficial bladder cancer using intravesical administration 
was commissioned in 2001 and sponsored by Spectrum Pharmaceuticals 
(Irvine, California). Significant anti-tumour activity was reported in the phase 
I/II study (Puri et al., 2006) and this was subsequently confirmed in phase II 
studies (van der Heijden et al., 2006). Phase III trials are currently underway 
and the results are expected in the first quarter of 2012. The purpose of this 
article is to review the pharmacology of EO9, its preclinical and clinical history 
and to discuss the potential implications that this story has for the 
development of other loco-regional therapies.  
 
Pharmacology of EO9.  
EO9 is activated by several enzymes, the most widely studied of these is 
NAD(P)H:Quinone oxidoreductase 1 (NQO1 or DT-diaphorase). NQO1 is a 
cytosolic flavoprotein that catalyses the two electron reduction of a wide range 
of substrates (Ernster, 1987) and its physiological function is detoxification of 
quinones (Cadenas, 1995). The chemistry of the side chains attached to the 
quinone nucleus dictates the reactivity of the reduced form (Cadenas, 1995) 
and in the case of EO9, it is reduced to a DNA damaging species. In cell free 
systems, reduction of EO9 by NQO1 results in the generation of DNA damage 
in the form of single strand breaks (Walton et al., 1991). Catalase inhibits this 
process (Phillips et al., 1999) suggesting that hydrogen peroxide is formed 
during the redox cycling of the EO9 hydroquinone in oxygen (Bailey et al., 
1998; Butler et al., 1996). Alkylation of DNA is possible via the release of 
hydroxyl groups at C2 and C3 as well as protonation and opening of the 
aziridine ring (Hargreaves et al., 2000). DNA inter-strand cross links (ICL) 
following the reduction of EO9 by purified rat NQO1 under hypoxic conditions 
have been reported (Maliepaard et al., 1995) although other groups have not 
observed ICLs following reduction by purified human NQO1 under aerobic 
conditions (Phillips, 1996). Limited information exists about the formation of 
mono-adducts. Other purified enzymes have been shown to reduce EO9 and 
induce either single strand breaks or DNA cross links including xanthine 
oxidase (Maliepaard et al., 1995) and NADPH cytochrome P450 reductase 
(Bailey et al., 2001).     
  
In cell based assays, EO9 does not behave as a classical hypoxia targeted 
bioreductive drug as it also has activity against aerobic cells (Collard et al., 
1995; Hendriks et al., 1993; Phillips et al., 1992; Plumb et al., 1994a; Roed et 
al., 1989; Smitskamp-Wilms et al., 1994). Activation of EO9 still conforms to 
the concept of ‘enzyme directed bioreductive therapy’ (Workman et al., 1990) 
as therapy could still be targeted at tumours that expressed high levels of 
NQO1. The role of NQO1 in activating EO9 to DNA damaging species in cell 
free assays is clear but its role in determining cellular response is more 
complex. Under aerobic conditions, good correlations between NQO1 activity 
and chemosensitivity in vitro have been reported (Collard et al., 1995; 
Fitzsimmons et al., 1996; Plumb et al., 1994b; Plumb et al., 1994c; Robertson 
et al., 1994; Robertson et al., 1992; Smitskamp-Wilms et al., 1994). In hypoxia 
however, significant potentiation of EO9’s activity was only seen in cell lines 
that lack NQO1 activity (Plumb et al., 1994b; Plumb et al., 1994c; Robertson 
et al., 1994). In cell lines where NQO1 was high, EO9 was as effective against 
aerobic and hypoxic cells. Mechanistically, it is likely that one electron 
reductases play a prominent role in the hypoxia selectivity whereas reduction 
of EO9 by NQO1 is an oxygen independent process (Workman, 1994). EO9 
can therefore be used to target the hypoxic regions of NQO1 deficient 
tumours whereas in NQO1 rich tumours, EO9 will target both the aerobic and 
hypoxic fraction. This feature of EO9’s pharmacology was seen as a unique 
and attractive feature as it suggested that EO9 has the capacity to exhibit 
single agent activity against solid tumours (Hendriks et al., 1993). These 
preclinical studies also suggested that EO9 might find its optimal use in 
combination with radiation or other drugs. 
 
In animal tumour models, EO9 was inactive against the P388 murine 
leukaemia but exhibited anti-tumour activity against human tumour xenografts 
and the generally chemo-resistant murine adenocarcinomas of the colon 
(MAC) tumours (Collard et al., 1995; Hendriks et al., 1993; Roed et al., 1989). 
Initial evidence that in vivo response correlated with NQO1 activity (Walton et 
al., 1992) was not substantiated in subsequent studies where poor 
relationships between NQO1 activity and in vivo activity were reported 
(Collard et al., 1995; Cummings et al., 1998). EO9 was selected for clinical 
evaluation based upon its novel mechanism of action (which was distinct from 
MMC), its preferential activity against cells derived from solid tumours in vitro 
and in vivo, its ability to target both aerobic and hypoxic cells and the lack of 
myelosuppression in mice and rats (Hendriks et al., 1993).  
 Clinical evaluation: Two phase I trials started in 1992 under the auspices of 
the EORTC. In the first study, the maximum tolerated dose following a three 
week schedule (q3wk) of 5 min intravenous infusion was 27 mg/m2 (Schellens 
et al., 1994). Bone marrow suppression was not observed and the dose 
limiting toxicity was reversible proteinuria. In a second phase I trial using a 
weekly bolus intravenous schedule (q1wk), a maximum tolerated dose of 14 
mg/m2 was reported and the dose limiting toxicity was again reversible 
proteinuria (Aamdal et al., 2000; McLeod et al., 1996). Damage to glomeruli 
was observed in the clinical trial and this correlated with high levels of NQO1 
in the kidney (Segura-Aguilar et al., 1994; Zappa et al., 2003). A total of three 
partial responses were recorded in the phase I studies; two in patients with 
adenocarcinoma of unknown primary site and one in a patient with bile duct 
cancer. Phase II clinical trials commenced in the summer of 1994 and two 
studies were conducted. In the first, a total of 92 patients with advanced 
breast, gastric, pancreatic and colorectal cancer were treated with a 5 min 
intravenous infusion of EO9 at a weekly dose of 12 mg/m2 (Dirix et al., 1996). 
No anti-tumour activity was seen. A second study involved the treatment of 38 
chemotherapy naïve patients with advanced non-small cell lung cancer 
(NSCLC). Two treatment schedules were evaluated; a single bolus 
intravenous injection at 12 mg/m2 administered weekly and intravenous bolus 
injection at 22 mg/m2 administered every three weeks. Dose limiting toxicity 
was reversible proteinuria and whilst stable disease was reported in thirteen 
patients, these studies concluded that EO9 at these doses and schedules had 
no clinical activity against NSCLC (Dirix et al., 1996; Pavlidis et al., 1996).  
 
Reasons for EO9’s failure: In a critique of the design of the clinical studies 
conducted, Connors (Connors, 1996) highlighted certain key deficiencies in 
clinical trial design. These included the fact that NQO1and/or hypoxia were 
not measured in patient tumour samples, a fact that can be partially explained 
by an incomplete understanding of EO9s mechanism of action in the 1990’s 
when the trials were designed. Both these parameters are key determinants 
of EO9’s activity and it is conceivable that tumours lacked the appropriate 
biochemistry required for drug activation. This is however unlikely as high 
NQO1 expression and hypoxia is typically found in many solid tumours 
(Siegel et al., 1998; Siegel et al., 2000; Vaupel et al., 2001; Vaupel et al., 
2007). On the other hand, EO9 should have been evaluated in hypoxic 
tumours that lack NQO1 in combination with other modalities (such as 
radiotherapy) that target the aerobic fraction. Post irradiation treatment of 
tumours in vivo with EO9 indicated that radiosensitization was obtained in 
various preclinical tumour models (Adams et al., 1992; Burd et al., 2005) but 
no clinical trials of this nature were conducted. In any future trials of 
Apaziquone or other bioreductive drugs, it is therefore advised that levels of 
hypoxia and enzymology (particularly NQO1 in the case of apaziquone) 
should be measured so that they can be used as potential biomarkers to 
further stratify patient outcomes.  
 
In addition to concerns about the design of the clinical trials, attention also 
focused on whether or not drug delivery to tumours was impaired. The factors 
that determine how much drug is delivered to tumours can be broadly 
grouped into supply (extent of tumour vasculature and pharmacokinetics), flux 
(the drugs ability to penetrate through multiple layers of cells) and 
metabolism/sequestration of drugs within cells or the extracellular matrix 
(Minchinton et al., 2006).  In mice, the half life was 1.9 ± 0.1 min and the AUC 
was 4.8 μg.min/ml following the iv administration of EO9 at 12 mg/kg and in 
male Sprague-Dawley rats, the half life was 3.0 ± 0.2 min with an AUC of 6.2 
μg.min/ml following an iv dose of 3 mg/kg (Workman et al., 1992). The rapid 
clearance and extremely short half life of EO9 in rodents was replicated in 
man with half lives ranging from 0.8 to 19 min at the maximum tolerated dose 
of 27 mg/m2 administered intravenously (Schellens et al., 1994). Similar 
preclinical and clinical data were reported by other groups (Bibby et al., 1993b; 




Given this data, it was clear that the supply of EO9 to tumours is likely to be 
impaired by its poor PK properties. To some extent, poor PK can be offset if 
the ‘flux’ of drugs through avascular tissue is good but early studies using 3 
dimensional multilayered post-confluent cultures and multicell spheroids 
suggested that drug penetration barriers may exist (Bibby et al., 1993a; Pizao 
et al., 1993). Resistance in these models could be due to a multitude of 
reasons including low cell proliferation rates, reduced extracellular pH, 
reduced nutrient status etc. EO9 is however preferentially active against cells 
in acidic extracellular pH (Phillips et al., 1992), is able to kill confluent 
monolayer cultures (Phillips et al., 1997) and is active against hypoxic cells. In 
1996, Cowan et al (Cowan et al., 1996) described an assay that could 
quantify the rate at which drugs crossed multicell layers in vitro. EO9 is able to 
cross DLD-1 human colorectal cancer multicell layers but in comparison to 
tirapazamine (a nitroimidazole based bioreductive drug), its penetration rate is 
slow (Phillips et al., 1998). This study concluded that when EO9’s rapid 
pharmacokinetic elimination is taken into consideration, EO9 would only 
penetrate a few microns from a blood vessel within its pharmacokinetic 
lifespan and this is the probable reason for its failure to demonstrate efficacy 
in the clinic (Phillips et al., 1998).  
 
Whilst inadequate drug delivery to tumours appears a plausible explanation, 
the question remains as to why EO9 is active against preclinical tumour 
models (Hendriks et al., 1993) but inactive in clinical trials despite PK 
properties being similar in rodents and humans? A critical review of the 
preclinical studies however reveals that the magnitude of anti-tumour 
response observed is low with specific growth delays of only a few days 
reported. This level of activity would be acceptable if EO9 functioned purely 
as a hypoxia targeted agent as cytotoxic effects against hypoxic cells would 
be masked by the continued growth of the aerobic fraction of cells. In NQO1 
rich tumours however, EO9 would target the aerobic fraction of cells and in 
this case, a much greater level of activity would be expected. EO9 does 
induce some responses in preclinical tumours and partial responses and 
stable disease was seen in phase I and II studies (Pavlidis et al., 1996; 
Schellens et al., 1994) so some EO9 is reaching the tumour. Direct intra-
tumoural injection of EO9 results in improved anti-tumour activity (Loadman et 
al., 2002) supporting the fact that sub-optimal concentrations of EO9 reach 
tumours following systemic administration.   
 Clinical evaluation of EO9 against superficial bladder cancer: Based 
upon this understanding of why EO9 failed, investigators were presented with 
two options; to develop analogues of EO9 that retained its good PD properties 
but had improved PK properties (Loadman et al., 2002; Phillips, 1996; Phillips 
et al., 2004; Phillips et al., 1999) or utilise EO9’s bad properties to our 
advantage. In this latter case, loco-regional administration of drug would 
circumvent the problem of drug delivery and if the drug could be retained at 
this site for long periods, improved penetration into the tumour would occur. 
Furthermore, any drug that reached the systemic circulation would be rapidly 
cleared thereby reducing the risk of systemic toxicity. Superficial transitional 
cell carcinoma (TCC) of the bladder provided a suitable clinical model to test 
this hypothesis as intravesical administration of chemotherapy or 
immunotherapy following transurethral resection (TUR) is an established 
mode of treatment (Hall et al., 2007). Following studies which demonstrated 
that TCC of the bladder expressed the key biochemical machinery required to 
activate EO9 (figure 2) (Basu et al., 2004; Choudry et al., 2001), a phase I/II 
pilot study commenced in 2004.  
 
The purpose of this trial was to establish the dose of EO9 (now renamed 
EOquin by the sponsor Spectrum Pharmaceuticals which was later changed 
to Apaziquone) that could be safely administered intravesically and obtain 
evidence of efficacy against a marker lesion left in situ at TUR (Gofrit et al., 
2010; Puri et al., 2006). Six patients with multifocal superficial TCC of the 
bladder received escalating doses of EO9 (0.5 – 16 mg/40ml) administered 
intravesically which was retained within the bladder for 1 hour. EO9 was well 
tolerated at doses up to 4 mg/40ml and grade 2 and 3 dysuria and haematuria 
was observed at doses at or above 8 mg/40ml. No EO9 could be detected in 
plasma (Puri et al., 2006). A further 6 patients received EO9 at 4 mg/40ml 
once a week for 6 weeks which was well tolerated in all cases. Analysis of 
EO9 in the urine at the end of the instillation demonstrated that the 
concentration increased linearly with dose and therapeutically effective 
concentrations were being achieved (Puri et al., 2006). At 4 mg/40ml (100 
μg/ml), the concentration of EO9 in the urine at the end of the1 hour 
instillation was 72. 2 ± 11.8 μM (20.79 μg/ml) which represents a significant 
increase in drug exposure parameters compared to those reported following 
intravenous administration (table 1). A total of 8 out of 12 patients had 
complete remission as defined by complete loss of the marker lesion, 
negative cytology and histology at the site of the lesion (Puri et al., 2006). 
Representative images of the marker lesion in situ before and after EO9 are 
presented in figure 2.  
 
Phase II studies were conducted using an identical study design to the phase 
I/II pilot study and each patient received 6 weekly intravesical instillations of 
EO9 at 4 mg/40ml with the first instillation starting two weeks after TUR (van 
der Heijden et al., 2006). EO9 was well tolerated with no systemic side effects 
and grades 1 to 3 dysuria and haematuria being the most common local side 
effects. Of a total of 45 patients with superficial TCC of the bladder, 30 (67%) 
patients had complete response as defined by complete macro- and 
microscopic elimination of a marker lesion (van der Heijden et al., 2006). 
Recurrence free rates were good in comparison to the results of other ablative 
studies (Hendricksen et al., 2009; Jain et al., 2009). EO9 was reformulated in 
2007 (van der Schoot et al., 2007a; van der Schoot et al., 2007b; van der 
Schoot et al., 2008) and it is currently undergoing phase III clinical evaluation 
in multiple centres across North America and Europe. Additionally, studies 
where EO9 was administered within 24 hours of TUR which is the standard 
recommended treatment for superficial TCC of the bladder (Sylvester et al., 
2004) demonstrated that EO9 was well tolerated and has a good safety profile 
(Hendricksen et al., 2008).   
 
Conclusions and future prospects:  
EO9 has had a chequered history but by understanding the reasons why it 
failed, EO9 has been transformed from a clinically inactive drug to one that 
has efficacy against superficial bladder cancer. The outcome of the phase III 
clinical trials is eagerly anticipated but even so, the ‘EO9 story’ demonstrates 
that compounds with poor systemic PK could be effectively used in a loco-
regional setting. In the case of EO9, direct intravesical administration 
circumvented the drug delivery problem encountered following intravenous 
administration and resulted in high concentrations of drug that are confined 
within the bladder. In this setting, EO9’s poor PK properties were 
advantageous as any drug that reached the blood stream was rapidly cleared. 
Whilst this review has focused specifically on EO9, our experience with EO9 
has potentially significant implications for the development of loco-regional 
therapies in general. We suggest that compounds with good PD properties 
but poor systemic PK could be valuable therapeutic agents for treating 
cancers in a loco-regional setting.  
 
Loco-regional chemotherapy is emerging as an important adjunct to surgery 
and systemic chemotherapy in selected patients with certain types of cancer 
(Ceelen et al., 2010; Lu et al., 2010). In addition, as early detection strategies 
for cancer become more effective, there is a case for using loco-regional 
chemotherapy as an adjunct to surgical excision. Therapeutic agents used for 
loco-regional therapies are typically conventional chemotherapeutic that are 
widely used to treat systemic disease. These can be effective but the success 
of this approach has been restricted by local toxicity, inadequate drug 
penetration and systemic toxicity caused by drugs leaching out from the site 
of administration into the blood stream (Lu et al., 2010; Masters et al., 1996; 
Masters et al., 1990). In terms of selecting drugs for use in a loco-regional 
setting, experience with EO9 has shown that compounds with poor systemic 
PK can be locally efficacious without the systemic toxic side effects observed 
when administered intravenously. In the context of the majority of drug 
discovery programs, compounds with poor systemic PK are typically rejected 
during the process of lead compound optimisation and currently reside on the 
medicinal chemists shelves. Based upon our experience with EO9, we 
suggest that many of these compounds should be revisited and re-evaluated 
as potential loco-regional therapies.      
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 Table 1. Summary of pharmacokinetic parameters following the intravenous 
administration of EO9 (5 min infusion) and intravesical administration (one 
hour instillation) at maximum tolerated doses. The values quoted following 
intravenous administration refer to plasma levels whereas following 





















      
Intravenous* 
 
27 mg/m2 1.418 ± 0.911 4.92 ± 3.16 0.468 7.8 ± 5.6 
Intravesical# 4mg/40ml 100.00 347.2 204.8 36.6 
      
 
* Data obtained from Schellens et al (Schellens et al., 1994) 




















Legends to figures 
Figure 1. Chemical structure of EO9 (A) and scheme for possible activation of 
EO9 leading to DNA damage (B). 2e and 1e in panel B represent 2 electron 
reduction (via enzymes such as NQO1) and 1 electron reduction (via 
enzymes such as cytochrome P450 reductase) respectively. Q, SQ and HQ 
denote Quinone (parent compound), Semi-Quinone (1 electron reduction 
product) and Hydroquinone (2 electron reduction product) respectively.  
 
 Figure 2. Representative immunohistochemical analysis of superficial human 
TCC of bladder expressing high levels of NQO1 (A), Glucose transporter 1 
(Glut-1) (B) and pimonidazole treated tumour (C). Glut-1 and pimonidazole 
have been used as endogenous and exogenous markers of hypoxia 
respectively (Rademakers et al., 2011). The brown staining in panels A to C 
represents areas of positive staining. Appearance of marker lesion (ML) in situ 
before (D) and after (E) a 6 week course of EO9 administered intravesically 
once a week at a dose of 4 mg/40ml.         
 
